A dual source lactoferrin composition and formula

Abstract

The present application provides a dual-source lactoferrin composition and a formula food. The dual-source lactoferrin composition comprises bovine lactoferrin and camel lactoferrin. The dual-source lactoferrin composition can overcome the limitations of single-source lactoferrin in the prior art in terms of antibacterial effect, cost and functional suitability, and the formula food comprising the dual-source lactoferrin composition has excellent antibacterial property, solubility and stability, and has excellent market application prospect.

Description

Technical Field

[0001] This invention relates to the field of dairy product technology, specifically to a dual-source lactoferrin composition and formulated food. Background Technology

[0002] Lactoferrin (LF) is a multifunctional iron-binding glycoprotein widely found in the milk of mammals, possessing various biological activities such as antibacterial, antiviral, immunomodulatory, and antioxidant properties. It is widely used in food, pharmaceuticals, health products, and cosmetics. In these applications, the breadth of its antibacterial spectrum, the intensity of its antibacterial activity, its stability (e.g., thermal stability, resistance to digestive enzymes), and cost control are key requirements. However, existing single-source lactoferrins (such as bovine lactoferrin, bLF) have significant limitations in terms of antibacterial efficacy, cost, and functional adaptability. Summary of the Invention

[0003] In view of this, the present invention provides a dual-source lactoferrin composition that can overcome the limitations of single-source lactoferrin in terms of antibacterial effect, cost and functional adaptability in the prior art. In addition, the formulated food products containing the dual-source lactoferrin composition have excellent antibacterial properties, solubility and stability, and have excellent market application prospects.

[0004] A first aspect of the present invention provides a dual-source lactoferrin composition, comprising bovine lactoferrin and camel lactoferrin.

[0005] The dual lactoferrin composition as described above, wherein the mass ratio of the bovine lactoferrin to the camel lactoferrin is (0.25-4):1.

[0006] The dual-source lactoferrin composition described above also includes prebiotics.

[0007] The dual-source lactoferrin composition as described above, wherein the prebiotic includes at least one of resistant dextrin, galactooligosaccharide, isomaltooligosaccharide, inulin, fructooligosaccharide, isomerized lactose, xylooligosaccharide, and polydextrose.

[0008] The dual-source lactoferrin composition as described above, wherein the prebiotic content in the dual-source lactoferrin composition is 75-99.9% by mass.

[0009] The dual-source lactoferrin composition as described above, wherein the camel-derived lactoferrin is derived from raw camel milk and / or whole camel milk powder.

[0010] The dual lactoferrin composition described above also includes vitamin C.

[0011] The dual lactoferrin composition as described above, wherein the vitamin C content in the dual lactoferrin composition is 0.005-0.2% by mass.

[0012] The dual lactoferrin composition described above, wherein the bovine lactoferrin and the camel lactoferrin are encapsulated by microcapsules; and / or,

[0013] The dual-source lactoferrin composition is liquid and also includes sodium alginate.

[0014] The dual-source lactoferrin composition as described above, wherein the minimum inhibitory concentration of the dual-source lactoferrin composition against bacteria is ≤50 μg / mL; and / or,

[0015] The minimum inhibitory concentration of the dual-source lactoferrin composition against fungi is less than or equal to 80 μg / mL.

[0016] A second aspect of the present invention provides a formulated food product comprising the dual-source lactoferrin composition as described above.

[0017] This invention combines camel-derived lactoferrin with bovine-derived lactoferrin, utilizing their differences in molecular structure (such as the complex glycosylation modification and superior thermal stability of camel-derived lactoferrin) and functional complementarity (the mature application foundation of bovine-derived lactoferrin and the broad-spectrum antibacterial properties of camel-derived lactoferrin), thus solving the technical problems of narrow antibacterial spectrum, high cost, and poor stability of lactoferrin from single sources. Detailed Implementation

[0018] The technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0019] In current technologies, research and application of lactoferrin mainly focus on bovine lactoferrin (bLF), which is derived from milk and has a relatively high level of technological maturity. However, it has the following problems: Limited antibacterial spectrum: bLF has a strong inhibitory effect on Gram-positive bacteria (such as Staphylococcus aureus) and some Gram-negative bacteria (such as Escherichia coli), but its inhibitory effect on fungi (such as Candida albicans) is weak; Allergenicity problem: bLF may trigger allergic reactions in some people (such as IgE-mediated immune responses), limiting its application in sensitive populations; Cost-activity contradiction: Although bLF can be extracted through purification technology, the production cost of high-purity bLF is high, and the purification process may destroy its natural glycosylation structure, leading to a decrease in activity.

[0020] A first aspect of the present invention provides a dual-source lactoferrin composition comprising bovine lactoferrin and camel lactoferrin.

[0021] In this embodiment, by combining two lactoferrins from different sources, the technical problems of narrow antibacterial spectrum, high cost, or strong sensitization associated with single-source lactoferrin are solved by utilizing their differences in molecular structure (such as the complex glycosylation modification and superior thermal stability of camel-derived lactoferrin) and functional complementarity (the mature application foundation of bovine lactoferrin and the broad-spectrum antibacterial properties of camel-derived lactoferrin). Specifically, the glycan structure of camel-derived lactoferrin contains more sialic acid and fucose modifications, enabling it to maintain activity under high-temperature treatment or digestive enzyme action, while bovine lactoferrin ensures compatibility with camel-derived lactoferrin units through its conserved glycosylation sites.

[0022] In one specific embodiment, when the mass ratio of bovine lactoferrin to camel lactoferrin is (0.25-4):1, the advantages of both camel and bovine lactoferrin can be combined, resulting in a dual-source lactoferrin with a lower risk of sensitization, excellent antibacterial properties and thermal stability, and also with a lower cost, thus achieving a balance between cost and performance.

[0023] In one specific embodiment, the dual-source lactoferrin composition also includes prebiotics.

[0024] This embodiment addresses the dual requirements of solubility and functionality in the lactoferrin composition by adding prebiotics. Compared to adding other nutrients, the addition of prebiotics can improve the solubility of the dual-source lactoferrin composition by shortening the powder settling time through its high water-holding capacity, without significantly compromising the antibacterial properties of lactoferrin.

[0025] This invention does not specifically limit the prebiotic, and it can be any prebiotic commonly used in the art. In one specific embodiment, the prebiotic includes at least one of resistant dextrin, galactooligosaccharide, isomaltooligosaccharide, inulin, fructooligosaccharide, isomerized lactose, xylooligosaccharide, and polydextrose.

[0026] In this embodiment, the prebiotics mentioned above were selected based on the matching of their molecular structure and functional characteristics: the high heat resistance of resistant dextrin (which can withstand high-temperature treatment at 120°C) ensures its stability in the spray drying process; the low osmotic pressure of isomaltooligosaccharide (osmotic pressure of 0.35 osmol / kg) avoids irritation to the intestinal mucosa; the β-(2→1) glycosidic bond structure of inulin enhances the activity of probiotics through selective fermentation, selectively promoting the proliferation of Bifidobacteria and Lactobacilli. The short-chain fatty acids produced by the metabolism of these bacteria can further reduce the pH value of the intestine, thereby synergizing with the iron ion chelating ability of lactoferrin to inhibit the growth of pathogenic bacteria; the gel network formed by the high molecular weight of polydextrose (average molecular weight of 200,000 Da) can prolong the retention time of lactoferrin in the intestine, thereby improving the antibacterial effect.

[0027] In one specific embodiment, the prebiotic content in the dual-source lactoferrin composition is 75-99.9% by mass. This embodiment balances cost control and functional requirements through optimization of the mass percentage, ensuring that the dual-source lactoferrin composition contains sufficient lactoferrin and that the dual-source lactoferrin possesses both excellent solubility and antibacterial properties.

[0028] Furthermore, the prebiotic content can range from 85% to 95% by mass.

[0029] In one specific embodiment, the camel-derived lactoferrin is derived from raw camel milk and / or whole camel milk powder. This embodiment solves the problem of high extraction costs of camel-derived lactoferrin in the prior art by directly using raw camel milk and / or whole camel milk powder instead of purified camel-derived lactoferrin. In some embodiments, the lactoferrin content of raw camel milk is 58.43±3.92 g / L, and its naturally occurring casein and whey protein can act as natural stabilizers to prevent the aggregation of lactoferrin during processing.

[0030] In some embodiments, the dual-source lactoferrin composition may include, by weight parts: 700-999.9 parts of whole camel milk powder and / or raw camel milk (on a dry matter basis), and 0.1-1 parts of bovine lactoferrin.

[0031] In one specific embodiment, the dual-source lactoferrin composition further includes vitamin C. This embodiment addresses the oxidative degradation problem of lactoferrin during storage by adding vitamin C. The reducing power of vitamin C (E° = +0.17V) effectively inhibits the oxidation of tyrosine residues in lactoferrin, thereby maintaining its iron-binding capacity.

[0032] In some embodiments, the vitamin C content in the dual-source lactoferrin composition is 0.05-0.2% by mass.

[0033] In one specific embodiment, bovine lactoferrin and camel lactoferrin are encapsulated in microcapsules.

[0034] This embodiment addresses the problem of premature release of lactoferrin in the acidic gastric environment by employing microencapsulation technology (such as spray drying, with gelatin and gum arabic as the encapsulating agent). Microencapsulated lactoferrin releases only 15% of its active ingredient in simulated gastric fluid at pH 2.0, while releasing 85% in simulated intestinal fluid at pH 6.8, thus ensuring its targeted action in the intestine.

[0035] In another specific embodiment, the dual-source lactoferrin composition is liquid and also includes sodium alginate. For the liquid composition, sodium alginate forms an ionic bond with the lysine residues of lactoferrin through its carboxylic acid group (-COOH), forming a stable colloidal system and preventing precipitation of lactoferrin during storage. In some embodiments, the mass percentage of sodium alginate in the dual-source lactoferrin composition can be 0.5-2%.

[0036] In some embodiments, the dual-source lactoferrin composition can be prepared by a wet mixing process, for example, by homogenizing raw camel milk with a bovine lactoferrin solution (concentration 10 mg / mL) at 40°C (homogenization pressure 20 MPa), and then obtaining the dual-source lactoferrin composition in powder form by spray drying (inlet air temperature 180°C, outlet air temperature 85°C).

[0037] In this invention, the composition of the dual-source lactoferrin composition can be further selected to further improve its antibacterial properties. In some embodiments of this invention, the minimum inhibitory concentration of the dual-source lactoferrin composition against bacteria is ≤50 μg / mL; and / or,

[0038] The minimum inhibitory concentration of the dual-source lactoferrin composition against fungi is less than or equal to 80 μg / mL.

[0039] The bacteria include any of the Gram-positive and Gram-negative bacteria. Examples of Gram-positive bacteria include *Staphylococcus aureus* (BNCC186335) and *Propionibacterium acnes* (BNCC336649); examples of Gram-negative bacteria include *Escherichia coli* (BNCC185254) and *Pseudomonas aeruginosa* (ATCC9027). Fungi include *Cryptococcu sneoformans* (ATCC32719) and *Candida albicans* (ATCC10231).

[0040] The minimum inhibitory concentration (MIC) refers to the lowest concentration at which no visible bacterial growth is observed after culturing the dual-source lactoferrin composition, which includes the aforementioned bacteria and / or fungi, at 37°C for 24 hours.

[0041] A second aspect of the present invention provides a formulated food product comprising the above-described dual-source lactoferrin composition. The dual-source lactoferrin composition of this embodiment can be used in formulated foods, which can be dairy products such as milk powder, liquid milk, and yogurt, or non-dairy foods. The formulated food product can be suitable for infants, children, adults, or the elderly. In specific embodiments, the formulated food product can be, for example, infant formula or functional beverages.

[0042] This invention resolves the contradiction between broad-spectrum antibacterial activity and cost control in existing lactoferrin products by applying the first aspect of the dual-source lactoferrin composition to formulated foods.

[0043] In some embodiments, when the dual-source lactoferrin composition is applied to infant formula, the amount of the dual-source lactoferrin composition added can be 0.05-2 wt%; when the dual-source lactoferrin composition is applied to functional beverages, the amount of the dual-source lactoferrin composition added can be 0.1-1 wt%.

[0044] The present invention will be further described below with reference to specific embodiments.

[0045] Example 1

[0046] The dual-source lactoferrin composition of this embodiment was prepared by a method including the following steps:

[0047] Camel-derived lactoferrin, bovine lactoferrin, and demineralized whey powder D90 were dry-mixed to obtain a uniform powder, which is a dual-source lactoferrin composition.

[0048] The content of camel lactoferrin is 10% (10g / 100g), the content of bovine lactoferrin is 10% (10g / 100g), and the content of demineralized whey powder D90 is 80%. The mass ratio of camel lactoferrin to bovine lactoferrin is 1:1.

[0049] Example 2

[0050] The dual-source lactoferrin composition of this embodiment was prepared by a method including the following steps:

[0051] Camel lactoferrin, bovine lactoferrin and solid corn syrup were dry-mixed to obtain a uniform powder, which is a dual-source lactoferrin composition.

[0052] The content of camel lactoferrin is 5% (5g / 100g), the content of bovine lactoferrin is 5% (5g / 100g), and the content of solid corn syrup is 90%. The mass ratio of camel lactoferrin to bovine lactoferrin is 1:1.

[0053] Example 3

[0054] The dual-source lactoferrin composition of this embodiment was prepared by a method including the following steps:

[0055] Camel lactoferrin, bovine lactoferrin and solid corn syrup were dry-mixed to obtain a uniform powder, which is a dual-source lactoferrin composition.

[0056] The content of camel lactoferrin is 5% (4g / 100g), the content of bovine lactoferrin is 5% (1g / 100g), and the content of solid corn syrup is 95%. The mass ratio of camel lactoferrin to bovine lactoferrin is 4:1.

[0057] Example 4

[0058] The dual-source lactoferrin composition of this embodiment was prepared by a method including the following steps:

[0059] Whole camel milk powder, demineralized whey powder, bovine lactoferrin, and vitamin C are dry-mixed to obtain a uniform powder, which is a dual-source lactoferrin composition.

[0060] The content of whole camel milk powder is 72.535% (with 0.04g / 100g of camel lactoferrin), the content of demineralized whey powder is 27.3%, the content of bovine lactoferrin is 0.065% (0.05g / 100g), and the content of vitamin C is 0.1%. The mass ratio of camel lactoferrin to bovine lactoferrin is 4:5.

[0061] Example 5

[0062] The dual-source lactoferrin composition of this embodiment was prepared by a method including the following steps:

[0063] Camel lactoferrin, bovine lactoferrin and isomaltooligosaccharide were dry-mixed to obtain a uniform powder, which is a dual-source lactoferrin composition.

[0064] The content of camel lactoferrin is 10% (10g / 100g), the content of bovine lactoferrin is 10% (10g / 100g), and the content of isomaltooligosaccharide is 80%. The mass ratio of camel lactoferrin to bovine lactoferrin is 1:1.

[0065] Example 6

[0066] The dual-source lactoferrin composition of this embodiment was prepared by a method including the following steps:

[0067] Camel-derived lactoferrin, bovine lactoferrin, and resistant dextrin were dry-mixed to obtain a uniform powder, which is a dual-source lactoferrin composition.

[0068] The content of camel lactoferrin is 5% (5g / 100g), the content of bovine lactoferrin is 5% (5g / 100g), and the content of resistant dextrin is 90%. The mass ratio of camel lactoferrin to bovine lactoferrin is 1:1.

[0069] Example 7

[0070] The dual-source lactoferrin composition of this embodiment was prepared by a method including the following steps:

[0071] Camel lactoferrin, bovine lactoferrin and polydextrose were dry-mixed to obtain a uniform powder, which is a dual-source lactoferrin composition.

[0072] The content of camel lactoferrin is 4% (4g / 100g), bovine lactoferrin is 1% (1g / 100g), and polydextrose is 95%. The mass ratio of camel lactoferrin to bovine lactoferrin is 4:1.

[0073] Example 8

[0074] The dual-source lactoferrin composition of this embodiment was prepared by a method including the following steps:

[0075] Camel lactoferrin, bovine lactoferrin, isomaltooligosaccharide and inulin were dry-mixed to obtain a uniform powder, which is a dual-source lactoferrin composition.

[0076] The content of camel lactoferrin is 10% (10g / 100g), the content of bovine lactoferrin is 10% (10g / 100g), the content of isomaltooligosaccharide is 60%, and the content of inulin is 20%. The mass ratio of camel lactoferrin to bovine lactoferrin is 1:1.

[0077] Example 9

[0078] The dual-source lactoferrin composition of this embodiment was prepared by a method including the following steps:

[0079] Camel lactoferrin, bovine lactoferrin, and isomaltooligosaccharide were dry-mixed to obtain a uniform powder, which is a dual-source lactoferrin composition.

[0080] The content of camel lactoferrin was 0.1% (0.1g / 100g), the content of bovine lactoferrin was 0.05% (0.05g / 100g), and the content of isomaltooligosaccharide was 99.85%. The mass ratio of camel lactoferrin to bovine lactoferrin was 2:1.

[0081] Example 10

[0082] The dual-source lactoferrin composition of this embodiment was prepared by a method including the following steps:

[0083] Whole camel milk powder, resistant dextrin, bovine lactoferrin, and vitamin C are dry-mixed to obtain a uniform powder, which is a dual-source lactoferrin composition.

[0084] The whole camel milk powder contains 72.535% by weight (0.04g / 100g of camel lactoferrin), 27.3% by weight of resistant dextrin, 0.065% by weight of bovine lactoferrin (0.05g / 100g), and 0.1% by weight of vitamin C; the mass ratio of camel lactoferrin to bovine lactoferrin is 4:5.

[0085] Example 11

[0086] The dual-source lactoferrin composition of this embodiment was prepared by a method including the following steps:

[0087] Raw camel milk, isomaltooligosaccharide, bovine lactoferrin, and vitamin C are dry-mixed to obtain a uniform powder, which is a dual-source lactoferrin composition.

[0088] The raw camel milk contained 95.348% of the total mass (0.03g / 100g of camel lactoferrin), 4.624% of the total mass of isomaltooligosaccharide, 0.0111% of the total mass of bovine lactoferrin (0.05g / 100g), and 0.0169% of the total mass of vitamin C. The mass ratio of camel lactoferrin to bovine lactoferrin was 3:5.

[0089] Experimental Example 1

[0090] 1.1 Preparation of antibacterial solution

[0091] Sample 1: bLF: purified from cow's milk, purity ≥95%, powder sample;

[0092] Sample No. 2: cLF: isolated and purified from camel milk, purity ≥90%, powder sample;

[0093] Sample No. 3: A powder sample obtained by dry mixing at a mass ratio of bLF:cLF=4:1;

[0094] Sample No. 4: A powder sample obtained by dry mixing bLF:cLF at a mass ratio of 1:1;

[0095] Sample No. 5: A powder sample obtained by dry mixing at a mass ratio of bLF:cLF=1:4;

[0096] Sample No. 6: A powder sample obtained by dry mixing at a mass ratio of OsrhLF:cLF=1:1;

[0097] Sample No. 7: A powder sample obtained by dry mixing at a mass ratio of bLF:OsrhLF=1:1;

[0098] OsrhLF is a plant-derived recombinant human lactoferrin from Oryzasativa, with a purity of ≥95%, sourced from Wuhan Kangjian Biotechnology Co., Ltd.

[0099] Preparation of antibacterial solutions 1-7: Use sterile distilled water as solvent and samples 1-7 as solute to prepare antibacterial solutions with a concentration of 1 mg / mL. Then, dispense the solutions in small batches and store at -20℃ for later use.

[0100] 1.2 Preparation of bacterial suspension

[0101] Based on the broad-spectrum requirements, the following were selected: Gram-positive bacteria: Staphylococcus aureus (BNCC186335) and Propionibacterium acnes (BNCC336649); Gram-negative bacteria: Escherichia coli (BNCC185254) and Pseudomonas aeruginosa (ATCC9027); Fungi: Cryptococcus sneoformans (ATCC32719) and Candida albicans (ATCC10231).

[0102] Preparation of bacterial suspension: The above 6 bacteria were cultured in their respective liquid media at 37°C with shaking for 24 hours, and the bacterial concentration was adjusted to 5 × 10⁶ with their respective sterile media. 6 CFU / mL (bacteria) or 5×10 5 CFU / mL (fungi) was used as the bacterial suspension for experiments.

[0103] 1.3 In vitro antibacterial activity assay

[0104] Take a sterile 96-well cell culture plate, add 50 μL of each of the above six experimental bacterial suspensions to each well, and then add 100 μL of antibacterial solutions 1-7 in a serially diluted manner. Use buffer-only as a negative control group. Repeat the measurement three times. Incubate at 37℃ in the microplate with shaking at 900 rpm for 24 h. After incubation, measure the OD600 of each well using a multifunctional microplate. The lowest concentration at which no visible bacterial growth is observed is the minimum inhibitory concentration (MIC) for different samples. The results are shown in Table 1.

[0105] Table 1

[0106]

[0107] As shown in Table 1, 1) the MIC value of the mixture of the two lactoferrins was significantly lower than that of bLF or cLF alone, and the antifungal MIC of the composition including bLF and cLF was the lowest overall compared to bLF or cLF alone; 2) the composition including the two lactoferrins was effective against not only Gram-positive and Gram-negative bacteria, but also against fungi, while bLF and cLF had poor antifungal effects; 3) the MIC values ​​of the complexes formed by OsrhLF with bLF and cLF were almost no different from those of bLF and cLF alone, and the antibacterial range and efficacy of the complexes formed by OsrhLF with bLF and cLF were basically the same as those of the single components.

[0108] Experimental Example 2

[0109] The steps are basically the same as in Experimental Example 1, except that:

[0110] Antibacterial solutions were prepared by replacing samples 1-7 in Test Example 1 with the lactoferrin compositions from Examples 1-6, and the in vitro antibacterial activity is shown in Table 2.

[0111] Table 2

[0112]

[0113] Generally, the antibacterial properties of a bi-lactoferrin composition are slightly reduced when it includes other nutrients compared to a composition containing only bi-lactoferrin. Table 2 shows that at the same concentrations of bLF and cLF, the combination with prebiotics exhibits a wider antibacterial spectrum and a lower overall MIC value than the combination without prebiotics. This demonstrates that bLF and cLF combined with a certain proportion of prebiotics have better antibacterial effects, indicating that adding a certain amount of prebiotics can ensure the nutritional richness of the bi-lactoferrin composition with minimal impact on antibacterial performance.

[0114] Experimental Example 3

[0115] Solubility evaluation experiment

[0116] Take 15g of the dual-source lactoferrin powder from each example and set aside. Measure 90mL of 60℃ water and pour it into a 200mL beaker, then add the dual-source lactoferrin powder, recording the time taken from the moment the powder is added until it completely settles in the water (sinking time). Using a stirring rod, rotate along the container wall at a speed of 2 revolutions per second, clockwise for 15 seconds and counterclockwise for 15 seconds to obtain reconstituted milk. Pour 2mL of the reconstituted milk onto a petri dish and observe the protein denaturation points. Immediately pass the remaining reconstituted milk through a 40-mesh standard sieve, simultaneously swirling the bottom portion of the reconstituted milk in a vortex before pouring it in, observing the formation of clumps (if any clumps adhere to the bottom of the bottle, include them in the total amount on the sieve to determine the result), then rinse the sieve with 10mL of purified water.

[0117] Clumping Scoring Standards

[0118] No lumps: No lumps are visible to the naked eye, 10 points;

[0119] Micro-clumps: Clumps with a diameter ≤0.5cm and number <10, 8 points;

[0120] Small number of clumps: clumps with a diameter ≤0.5cm and a quantity of 10-15, score 6;

[0121] Large clumps: clumps with a diameter ≤ 0.5cm and a quantity > 15, score 4;

[0122] Extra large clumps: clumps with a diameter > 0.5cm, 2 points.

[0123] Protein denaturation point scoring criteria

[0124] No protein denaturation points: No protein denaturation points are visible to the naked eye, 10 points;

[0125] Micro-protein denaturation spots: Protein denaturation spots with a diameter ≤1mm and a number ≤10, score 8;

[0126] A small number of protein denaturation spots: protein denaturation spots with a diameter ≤1mm and a number of 10-40, score 6;

[0127] Numerous protein denaturation spots: Protein denaturation spots with a diameter > 1 mm and a number ≤ 15, score 4;

[0128] Excessive protein denaturation spots: Protein denaturation spots with a diameter >1mm and a number >15, 2 points.

[0129] The statistical results are shown in Table 3.

[0130] Table 3

[0131]

[0132] Table 3 shows that the bi-source lactoferrin composition formed by combining bLF and cLF with a certain proportion of prebiotics has a shorter powder settling time and higher scores for protein denaturation points and clumps. This demonstrates that combining bLF and cLF with a certain proportion of prebiotics can, on the one hand, make the powder settle faster and reduce the number of insoluble clumps after dissolution, thus improving the solubility of the bi-source lactoferrin composition; on the other hand, it can reduce the degree of protein denaturation when bLF and cLF are mixed with hot water.

[0133] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A dual-source lactoferrin composition, characterized in that, The composition consists of bovine lactoferrin, camel lactoferrin, and prebiotics; The mass ratio of bovine lactoferrin to camel lactoferrin is (0.25-4):1; The prebiotic content is 75-99.9% by mass.

2. The dual-source lactoferrin composition according to claim 1, characterized in that, The prebiotics include at least one of resistant dextrin, galactooligosaccharide, isomaltooligosaccharide, inulin, fructooligosaccharide, isomerized lactose, xylooligosaccharide, and polydextrose.

3. The dual-source lactoferrin composition according to claim 1, characterized in that, The camel-derived lactoferrin is derived from raw camel milk and / or whole camel milk powder.

4. The dual-source lactoferrin composition according to any one of claims 1-3, characterized in that, It also includes vitamin C.

5. The dual-source lactoferrin composition according to claim 4, characterized in that, In the dual-source lactoferrin composition, the mass percentage of vitamin C is 0.005-0.2%.

6. The dual-source lactoferrin composition according to claim 1, characterized in that, The bovine lactoferrin and the camel lactoferrin are encapsulated in microcapsules; and / or The dual-source lactoferrin composition is liquid and also includes sodium alginate.

7. A formulated food product, characterized in that, Includes the dual-source lactoferrin composition according to any one of claims 1-6.

Images